Pharming (PHAR) Common Equity (2018 - 2026)

Pharming (PHAR) has 8 years of Common Equity data on file, last reported at $270.5 million in Q2 2026.

• Quarterly Common Equity rose 12.92% year-over-year to $270.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $270.5 million (up 12.92% YoY) and the FY2025 annual result came in at $277.1 million, up 25.35% from the prior year.
• Common Equity improved to $270.5 million in Q2 2026, from $269.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $270.5 million in Q2 2026 to a low of -$0.02 in Q4 2025.
• A 5-year average of $197.8 million and a median of $212.6 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity jumped 104995.39% — and 2025, when it plunged 100.0%.
• Tracing PHAR's Common Equity over 5 years: stood at $204.6 million in 2022, then grew by 6.91% to $218.8 million in 2023, then advanced by 1.04% to $221.1 million in 2024, then sank by 100.0% to -$0.02 in 2025, then soared by 1803266666766.67% to $270.5 million in 2026.
• The last three Common Equity figures came in at $270.5 million (Q2 2026), $269.0 million (Q1 2026), and -$0.02 (Q4 2025), per Business Quant data.